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Abstract
The role of Chk1 in the cellular response to DNA replication stress is well established. However recent work indi-
cates a novel role for Chk1 in the suppression of apoptosis following the disruption of DNA replication or DNA
damage. This review will consider these findings in the context of known pathways of Chk1 signalling and poten-
tial applications of therapies that target Chk1.
Review
The orderly and accurate replication of DNA is essential
for the maintenance of genetic stability in cells. Cell
cycle checkpoints play a critical role in this process by
sensing DNA damage or aberrant replication structures
and then slowing entry into S-phase, progression
through S-phase, and mitosis to facilitate repair [1].
Recent work from a number of laboratories shows that
some of these checkpoint responses regulate apoptosis
in response to disruptions of DNA replication. Cell
death helps maintain genetic stability by eliminating
damaged cells that are not likely to be repaired. Thus a
balance between cell cycle arrest and repair and the
induction of cell death that is determined by check-
points is critical for the preservation of genetic integrity.
p53 plays a major role in the induction of apoptosis
through the transcriptional activation of proapoptotic
genes such as BAX and PUMA in response to DNA
damage [2-4]. Thus in tumour cells deficient in p53 the
balance between cell death and cell cycle arrest/repair is
compromised. If repair is incomplete or inaccurate,
genetic abnormalities may accumulate in p53-deficient
tumour cells in part because cells acquiring DNA
damage are no longer committed to death. Recently a
number of laboratories using very different approaches
have attempted to restore apoptotic responses in
tumour cells to make them more responsive to thera-
peutic agents. Intriguingly several of these efforts have
become focused on the checkpoint kinase, Chk1, as
being particularly critical for the control of apoptosis in
tumour cells. Here I will review recent work implicating
Chk1 as a key mediator of death in tumour cells in
response to the disruption of DNA replication.
The ATR-Chk1 pathway primarily responds to ssDNA
generated by DNA replication stress
Chk1 is critical to a wide range of responses to DNA
replication stress and some forms of DNA damage.
Chk1 is rapidly phosphorylated at several sites in an
Ataxia telangiectasia mutated and Rad3 related (ATR)-
dependent manner after inhibition of DNA replication
[5]. These post translational modifications are required
to trigger cell cycle checkpoints in S and G2 [6], sup-
press inappropriate firing of late or cryptic DNA replica-
tion origins [7], and maintain replication fork integrity
[8,9]. The roles of Chk1 in cell cycle checkpoints overlap
with those of another DNA damage response pathway
controlled by the Ataxia telangiectasia mutated (ATM)
protein and its downstream phosphorylation target
Chk2. For example, both Chk1 and Chk2 phosphorylate
Cdc25A targeting it for degradation by ubiquitin-
mediated proteolysis [6,10]. In the absence of Cdc25A
the Cdk2/cyclinE/A complex is inactive and S-phase
arrest ensues. However the two pathways respond to dif-
ferent signals: single stranded DNA (ssDNA) for ATR-
Chk1 and DNA double stranded breaks (DSBs), DNA
double stranded ends, or collapsed replication forks for
ATM-Chk2.
Although an expanding family of proteins appears to
be necessary for Chk1 activation, much work implicates
ssDNA generated by the inhibition of DNA replication
as being critical for the ATR-mediated activation of
Chk1. Replication progression is driven by the coordi-
nated action of the replication helicase and DNA repli-
cation complexes. Work with Xenopus laevis egg
extracts indicates that when replication is inhibited, the
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unwinding of DNA continues while the replication com-
plex is stalled leading to the generation of ssDNA [11].
This ssDNA is rapidly coated by replication protein A
(RPA) and the resulting RPA-ssDNA complex recruits
ATR through the ATR interacting protein (ATRIP) [12].
The heterotrimeric Rad9-Rad1-Hus1 (9-1-1) DNA
clamp is then loaded onto ssDNA regions by the Rad17-
RFC2-5 complex [13,14] and TopBP1 is recruited to the
stalled forks through its interactions with the 9-1-1 and
ATR-ATRIP complexes [15,16]. Other proteins (includ-
ing Claspin [17,18], Brit1/Mcph1 [19], and FANCM/
FAAP24 [20]) have been reported to be essential for the
efficient activation of Chk1. Still further proteins
(including FancJ [21] and Tim-Tipin [22]) appear to
influence Chk1 activation through their roles in the gen-
eration of ssDNA. In vitro biochemical studies of poten-
tial substrates for the initial DNA binding reactions
using static heteroduplex DNAs and Xenopus egg
extracts show that 5’ssDNA-dsDNA junctions arising on
either leading or lagging strands are most effective for
Chk1 activation [23,24]. Thus these studies implicate
primed ssDNA at stalled replication forks as being an
effective substrate for the activation of this damage
response pathway in this model system.
ssDNA generated during the repair of some types of
DNA damage also triggers Chk1 activation. End proces-
sing at ionizing radiation (IR)-induced DNA DSBs by
the Mre11-Rad50-NBS1 complex that is initiated by
ATM can generate ssDNA and activate Chk1 [25].
Cellular consequences of loss of Chk1
Although deletion of Chk1 in mouse ES cells is lethal
[26,27], many other cell types survive partial or com-
plete loss of Chk1 function. Chk1-/- chicken DT40 cells
remain viable although their growth is slowed (in part
due to an increase in the level of spontaneous apoptosis,
[28]). Additionally, Chk1 inhibitors are not uniformly
toxic to cells at concentrations where Chk1 function is
compromised and siRNA-mediated depletions of Chk1
do not invariably cause cell death [29-31]. However cells
with a defective Chk1 response show increased sensitiv-
ity to wide range of DNA damaging agents and replica-
tion inhibitors. This is particularly evident in the form
of an enhanced level of apoptosis in cells where Chk1
function is compromised by genetic knockouts, siRNA-
mediated depletions or treatment with Chk1 inhibitors
following exposure to agents that interfere with DNA
replication [29-31] (Figure 1). This apoptotic response is
caspase-3 dependent and appears to be initiated in cells
in early S phase [29,30]. The onset of apoptosis is not
rapid, Chk1 depleted cells become committed to death
by 16 to 24 h after exposure to the replication inhibitors
while Annexin V and caspase-3 induction occur some-
what later [32]. The response can be triggered in both
p53 proficient and deficient cell lines. It was reported
that primary human diploid fibroblasts treated with
Chk1 inhibitors did not show this apoptotic response
[29]. However there have been no further studies using
primary cells and this should be confirmed with other
cell types.
siRNA-mediated depletions of other DNA damage
response proteins indicate that the apoptotic response is
specific for cells defective in ATR-Chk1 signalling fol-
lowing disruption of DNA replication [33]. Tumour cell
lines depleted of ATR showed a similar apoptotic
response to replication inhibitors as the same cells
depleted of Chk1 and co-depletion of ATR and Chk1
had no further effect. In contrast depletion of compo-
nents of the ATM-mediated protein kinase cascade
(ATM, Chk2, NBS1, or MRE11) had no significant effect
on the apoptotic response to replication inhibitors. In
addition, apoptotic responses of immortalized fibroblasts
originating from individuals predisposed to cancer as a
result of inherited mutations of ATM or NBS1 were not
altered following treatment with replication inhibitors
relative to cells corrected for these defects. Loss of the
ATM-mediated signalling also does not alter the death
response in ATR or Chk1-depleted cells.
These observations contrast with the central role
played by the ATM-mediated protein kinase cascade in
the apoptotic response to IR (Figure 1). ATM is central
to the cellular response to DNA DSBs. In addition to its
role in cell cycle checkpoints, this signalling cascade
controls the onset of apoptosis following IR through the
p53-mediated transcriptional activation of pro-apoptotic
proteins such as BAX and PUMA [2-4]. Embryonic
fibroblasts obtained form ATM-/-, Chk2-/-, NBS1-/- or
p53-/- mice show defects in the induction of apoptosis
by IR. MEFs deficient in ATM are partially defective
while p53 deficient cells show a more complete resis-
tance to the induction of apoptosis [34,35] although
knockouts of both Chk2 and ATM show levels of apop-
tosis similar to those found in p53-/- cells [35]. Thus
both ATM-dependent and independent pathways regu-
late the induction of apoptosis by IR.
While IR-induced apoptosis is suppressed in p53 defi-
cient cells, recent work has shown that cell death can be
restored by depletion of Chk1 [31] (Figure 1). A mor-
pholino screen of p53 deficient zebrafish embryos
revealed that radiation-induced apoptosis could be
restored by knockdown of Chk1. Intriguingly this novel
death pathway was caspase-2 dependent and was not
affected by overexpression of bcl2/xl. In further contrast
to the caspase-3-dependent pathway triggered by repli-
cation inhibitors in the absence of Chk1, the response
to IR is dependent upon both ATM and ATR. This
death response is conserved in human p53 deficient
tumour cells. Depletion or inhibition of Chk1 in such
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tumour cells induced a caspase-2 dependent apoptotic
response that was not detected in a p53 proficient line
or in Chk1 depleted cells treated with replication inhibi-
tors. How caspase-2 induces apoptosis is not clear as it
is not an executioner caspase. Caspase-2 is thought to
function upstream to cleave and activate BID that in
turn causes mitochondrial outer membrane permeabili-
zation, cytochrome c release, and activation of execu-
tioner caspases [36]. However this mitochondrial
pathway does not appear to participate in the induction
of death by IR in the absence of Chk1. Nevertheless,
these findings reveal that Chk1 controls distinct cell
death pathways triggered by DNA damage or perturba-
tions of DNA metabolism.
Mechanism(s)
Precise molecular events initiating apoptosis in the
absence of Chk1 are not clear. Chk1 has a number of
roles in cells in response to DNA replication stress. We
have initially attempted to investigate this mechanism
by determining which of these roles is most critical for
the control of apoptosis. These studies indicate that the
role of Chk1 in the suppression of inappropriate firing
of replication origins is the primary determinant [37].
The main evidence for this is the suppressive effect of
Cdc45 depletion on apoptosis in Chk1-depleted cells.
Cdc45 is an essential co-factor for the replication heli-
case and a component of a protein complex involved in
DNA replication initiation in human cells [38,39].
Figure 1 Chk1 suppressed death pathways. Chk1 responds to DNA replication stress in an ATR-dependent manner to trigger S-phase
checkpoints, suppress inappropriate firing of late or cryptic DNA replication origins, and maintain replication fork integrity. When this ATR-Chk1
signalling pathway is suppressed cells show an enhanced level of apoptosis that appears to be the result of loss of control of replication origin
firing [37]. This death pathway is characterized by mitochondrial outer membrane permeabilization (MOMP) and caspase-3 activation but is
independent of p53 status [30]. The induction of apoptosis in p53 proficient cells is strongly ATM/p53-dependent. This death pathway
characterized by the p53-dependent induction of the proapoptotic proteins PUMA and BAX, MOMP, and caspase-3 activation. p53 deficient cells
have a much reduced death response following exposure to IR due to the protective effects of ATM- or ATR-mediated signalling pathways.
However in the absence of Chk1, such cells show a caspase-2-dependent apoptotic response that that bypasses Bcl-2, MOMP, and caspase-3
[31]. How caspase-2 triggers apoptosis is unclear as previous work suggests caspase-2 induces death through BID cleavage and MOMP [36]. In
the p53-/-Chk1 depleted cells this death pathway is not activated (X) by IR.
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Although both of these processes may be affected by
Cdc45 depletion, the effect of Cdc45 depletion on apop-
tosis [37]is only seen where inappropriate origin firing
occurs in cells depleted of Chk1 [7,37]. Consistent with
this hypothesis apoptosis is enhanced in cells defective
in the negative effector of origin firing, p21, following
Chk1 depletion and treatment with a replication inhibi-
tor [30].
We speculated that stalled forks may generate a signal
for cell death that is amplified when further replication
forks are arrested as a result of the inappropriate origin
firing in the absence of Chk1. A number of events asso-
ciated with the inappropriate origin firing have been
reported that could potentially provide such signals.
Early after the inhibition of DNA replication in Chk1
depleted or inhibited cells, enhanced levels of RPA and
gH2AX foci relative to controls cells can be detected
[32,37]. Since the formation of these foci is also depen-
dent upon the function of Cdc45, it is likely that this
accumulation is a result of inappropriately fired origins
in the absence of Chk1. At later times the RPA32 subu-
nit of RPA is hyperphosphorylated. This is followed by a
strong induction of gH2AX and persistent activation of
ATM and Chk2 [32]. Despite the very high level of
gH2AX seen in some of the cells (evident as a pan
nuclear staining of gH2AX), these cells do not have
detectable double strand breaks, consistent with pre-
vious reports for cells exposed to UV light [40]. Various
reports have implicated H2AX phosphorylation state
and the recruitment of proapoptotic cJun-N-terminal
kinase (JNK1) after DNA damage [41,42]. Yet the Chk1-
depleted cells showing the high levels of gH2AX are not
committed to apoptosis. They can restart DNA synthesis
if the replication inhibitor is removed but this does not
resume at the sites of gH2AX foci and these cells do not
appear to progress through S-phase [32]. Therefore,
sites of gH2AX staining may represent abandoned repli-
cation forks that cannot be restarted.
RPA is phosphorylated by cells in S phase [43] but
can be hyperphosphorylated at a number of sites in
response to some types of DNA damaging agents (e.g.
IR, UV, or MNNG, [44]) or DNA replication inhibitors
[45]. Recent work indicates that hyperphosphorylated
RPA co-localizes with the homologous recombination
(HR) repair protein Rad51 at sites of ssDNA following
treatment with a replication inhibitor and that the
hyperphosphorylated form of RPA is required for HR
and the maintenance of cell viability under these condi-
tions [45]. Although it cannot yet be ruled out that the
enhanced level of hyperphosphorylated RPA somehow
assumes a different role in Chk1 depleted cells where
HR is compromised [9], these data suggest that
hyperphosphorylated RPA also contributes to cell survi-
val rather than death. So, the identity of a putative cell
death “signal transducer” remains elusive.
Therapeutic applications
An exciting implication of this work is that tumour cells
retain a cryptic apoptotic pathway that can be triggered
by therapeutic replication inhibitors or even radiother-
apy when Chk1 function is inhibited. Nevertheless the
use of Chk1 inhibitors in therapy has not met with uni-
versal enthusiasm because of the important role played
by Chk1 in the maintenance chromosomal stability and
viability in dividing cells. A mouse strain in which Chk1
was specifically disrupted in adult mammary cells
showed enhanced apoptosis and developmental defects
[46]. Conditional Chk1 heterozygosity in these cells
caused inappropriate cell cycle transitions and chromo-
somal abnormalities. Chk1 is highly expressed in many
types of tumours [47] and this may protect them from
replication stress induced by hypoxia or nutrient depri-
vation during tumour development [48] or the conse-
quences of inappropriate transitions into S-phase
triggered by genetic alterations acquired by tumour
cells. The Chk1 knockdown experiments suggest
enhanced lethality for tumour cells may be obtained
where the protein is only transiently depleted, thus
reducing potential lethality and genetic instability in
normal tissue caused by complete loss of Chk1 or long
term haploinsufficiency as in the conditonally heteroz-
ygous mice. Recent work has shown that Chk1 inhibi-
tors can be used to increase the sensitivity of tumour
cells to replication inhibitors in vitro and in vivo [49].
However initial studies using the nonspecific Chk1 inhi-
bitor UCN-01 met complications in the form of a much
increased half life in human serum due to an unfavour-
able association with human a-acid glycoprotein [50].
These difficulties may be overcome through the use of
new and more specific Chk1 inhibitors [51] and several
of these are already in phase I and II trails. It will be
interesting to see whether the higher specificity of these
agents improves the response.
An additional therapeutic application of Chk1 inhibi-
tors was revealed by an siRNA screen for gene silen-
cings synthetically lethal with Chk1 inhibition [52]. This
screen identified genes required for Fanconi anemia
pathway function as being particularly important for cell
survival when Chk1 function was inhibited. Strikingly
the effect of Chk1 inhibition and cisplatin in FA defi-
cient cell lines was synergistic, suggesting that Chk1
inhibitors may be useful for the treatment of tumours
containing mutations of FA genes or in combination
with novel FA pathway inhibitors.
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Conclusions
Clearly much remains to be done to understand the
mechanism(s) underlying Chk1 suppressed cell death.
While findings thus far provide strong support for the
use of Chk1 inhibitors in therapy, elucidation of
mechanism(s) underlying Chk1 suppressed death may
reveal novel therapeutic targets that may help overcome
the resistance that frequently accompanies such targeted
therapies.
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